Literature DB >> 7173293

Components of variability in serum theophylline concentrations during maintenance therapy with a sustained release formulation.

H Halkin, A Mazar, S Almog, Y Schnaps.   

Abstract

Fifteen adult chronic asthmatic patients were studied on 6 consecutive days of the second week of treatment with a new sustained release theophylline formulation, and 8 were again studied after three months on the same dosing regimen (375 mg b.i.d.). Serum theophylline concentrations were maintained in the therapeutic range (peak - 19.7 +/- 5.0 micrograms/ml; trough - 13.0 +/- 3.2 micrograms/ml) throughout the 12 hour dosing interval, and were greater than 75% of the peak concentration over 8.6 +/- 2.9 h. A degree of drug accumulation was evident in that the 1-h and 5-h levels rose from 12.2 +/- 4.1 and 4.5 +/- 4.8 micrograms/ml during the second week to 16.9 +/- 4.6 and 18.4 +/- 4.5 micrograms/ml, respectively, at three months. Between-patient differences accounted for 61%-71% of the total variation in steady state theophylline concentrations. After accounting for differences due to sampling time and assay error, unexplained random, within-individual variability amounted to 11%-18% of the total. Quantitative estimation of these components of variability may be incorporated into dosage forecasting methods based on single determinations of serum concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173293     DOI: 10.1007/bf00547558

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration.

Authors:  W A Colburn; D Shen; M Gibaldi
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

2.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

3.  Bioavailability and efficacy of a sustained-release theophylline tablet.

Authors:  P A Mitenko; R I Ogilvie
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

4.  Use of a twelve-hour theophylline preparation in chronic adult asthmatics.

Authors:  D Tinkelman; G Vanderpool; M S Carroll; D L Spangler
Journal:  Ann Allergy       Date:  1979-09

5.  The relation of product formulation to absorption of oral theophylline.

Authors:  M Weinberger; L Hendeles; L Bighley
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

6.  Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.

Authors:  W J Jusko; M J Gardner; A Mangione; J J Schentag; J R Koup; J W Vance
Journal:  J Pharm Sci       Date:  1979-11       Impact factor: 3.534

7.  Pharmacokinetics of a sustained-release theophylline formulation.

Authors:  P W Trembath; S W Boobois
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

8.  Prediction of maintenance dose required to attain a desired drug concentration at steady-state from a single determination of concentration after an initial dose.

Authors:  J T Slattery; M Gibaldi; J R Koup
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

9.  Pharmacokinetics of sustained release theophylline in low and high multidose regimens.

Authors:  G H Koëter; J H Jonkman; K de Vries; R Schoenmaker; J E Greving; R A de Zeeuw
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

10.  Modelling theophylline response in individual patients with chronic bronchitis.

Authors:  B Whiting; A W Kelman; J Barclay; G J Addis
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

View more
  3 in total

1.  Theophylline pharmacokinetics following single and repeated administration of slow-release capsules.

Authors:  J Torrent; I Izquierdo; M J Barbanoj; R Obach; M Nomen; F Jane
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

2.  Individualizing theophylline dosage: evaluation of a single-point maintenance dose prediction method.

Authors:  J H Wilkens; H Neuenkirchen; G W Sybrecht; M Oellerich
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Lack of influence of an intensive antacid regimen on theophylline bioavailability.

Authors:  R C Reed; H J Schwartz
Journal:  J Pharmacokinet Biopharm       Date:  1984-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.